Stocks and Investing Stocks and Investing
Tue, May 23, 2023

Charles Duncan Maintained (STOK) at Buy with Increased Target to $25 on, May 23rd, 2023


Published on 2024-10-28 03:57:07 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Maintained "Stoke Therapeutics, Inc." (STOK) at Buy with Increased Target from $20 to $25 on, May 23rd, 2023.

Charles has made no other calls on STOK in the last 4 months.



There are 6 other peers that have a rating on STOK. Out of the 6 peers that are also analyzing STOK, 1 agrees with Charles's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Greg Harrison of "B of A Securities" Upgraded from Sell to Hold and Increased Target to $12 on, Monday, May 1st, 2023


These are the ratings of the 5 analyists that currently disagree with Charles


  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $35 on, Friday, May 5th, 2023
  • Joseph Stringer of "Needham" Reiterated at Strong Buy and Held Target at $20 on, Friday, May 5th, 2023
  • Judah Frommer of "Credit Suisse" Reiterated at Buy and Held Target at $28 on, Friday, May 5th, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $24 on, Wednesday, April 26th, 2023
  • Laura Chico of "Wedbush" Maintained at Buy with Decreased Target to $25 on, Tuesday, March 7th, 2023
Contributing Sources